- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04509050
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children (BEGIN)
A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact in children with cystic fibrosis (CF) on endocrine growth factors and height, gastrointestinal function and gut microbiome, lung function and respiratory microbiome, liver and pancreatic function, sweat chloride, inflammatory markers, and bone health.
Total duration of the study is expected to be 6 years. Part A will be a prospective cross-sequential study to describe the natural history of hormonal growth factors in early childhood and assess the feasibility of additional measurements. In Part A, subjects will have up to 6 visits over a period of up to 3 years.
Part B will be a prospective longitudinal study to observe the effects of administration of either ivacaftor or elexacaftor/tezacaftor/ivacaftor (elex/tez/iva) on growth. In Part B, subjects will have one "before ivacaftor or elex/tez/iva" visit within 30 days before initiation of the therapy and five "after ivacaftor or elex/tez/iva" visits over a 24-month follow-up period.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Rachael Buckingham
- Phone Number: 206-884-7517
- Email: rachael.buckingham@seattlechildrens.org
Study Contact Backup
- Name: Nicole Rogers
- Phone Number: 206-884-7554
- Email: nicole.rogers@seattlechildrens.org
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- The Children's Hospital Alabama, University of Alabama at Birmingham
-
Contact:
- Justin Wade
- Email: jdwade@uabmc.edu
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
Contact:
- Mary Cross
- Email: mary.cross@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Active, not recruiting
- Nemours Children's Clinic
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Alejandra Weisman
- Email: a.weisman1@miami.edu
-
Orlando, Florida, United States, 32827
- Active, not recruiting
- The Nemours Children's Clinic - Orlando
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Hospital for Children
-
Contact:
- Lisa Bendy
- Email: lbendy@iupui.edu
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
Contact:
- Mary Teresi
- Email: mary-teresi@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Robert Fowler
- Email: Robert.Fowler@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Active, not recruiting
- University of Michigan, Michigan Medicine
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Helen DeVos Children's Hospital
-
Contact:
- Heather Mulroy
- Email: heather.mulroy@spectrumhealth.org
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Children's Hospitals and Clinics of Minnesota
-
Contact:
- Camerone Bey
- Email: Camerone.bey@childrensmn.org
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- The Minnesota Cystic Fibrosis Center
-
Contact:
- CF Trials Contact
- Email: cftrials@umn.edu
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Kansas City
-
Contact:
- Candy Schmoll
- Email: cschmoll@cmh.edu
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- St. Louis Children's Hospital
-
Contact:
- Tina Hicks
- Email: hickst@wustl.edu
-
-
New York
-
Buffalo, New York, United States, 14203
- Active, not recruiting
- The Cystic Fibrosis Center of Western New York
-
New York, New York, United States, 10032
- Recruiting
- Children's Hospital of New York
-
Contact:
- Hossein Sadeghi
- Email: HS762@cumc.Columbia.edu
-
Syracuse, New York, United States, 13210
- Recruiting
- SUNY Upstate Medical University
-
Contact:
- Mary Forell
- Email: forellm@upstate.edu
-
Valhalla, New York, United States, 10595
- Active, not recruiting
- New York Medical College at Westchester Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Kelly Thornton
- Email: Kelly.Thornton@cchmc.org
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Contact:
- Diana Gilmore
- Email: diana.gilmore@nationwidechildrens.org
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Active, not recruiting
- Oklahoma Cystic Fibrosis Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health Sciences University
-
Contact:
- Brendan Klein
- Email: kleinb@ohsu.edu
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Active, not recruiting
- Hershey Medical Center Pennsylvania State University
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Erin Donnelly
- Email: Donnellye4@email.chop.edu
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Children's Hospital of Pittsburgh of UPMC
-
Contact:
- Elizabeth Hartigan
- Email: elizabeth.hartigan@chp.edu
-
-
Texas
-
Dallas, Texas, United States, 75247
- Recruiting
- University of Texas Southwestern / Children's Health
-
Contact:
- Daniyal Kamal
- Email: Daniyal.Kamal@childrens.com
-
Fort Worth, Texas, United States, 76104
- Active, not recruiting
- Cook Children's Medical Center
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Baylor College of Medicine
-
Contact:
- Katie Howe
- Email: klhowe@texaschildrens.org
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Recruiting
- Primary Children's Cystic Fibrosis Center
-
Contact:
- Jane B Vroom
- Email: jane.vroom@hsc.utah.edu
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Active, not recruiting
- Vermont Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Active, not recruiting
- University of Virginia
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Sharon McNamara
- Email: sharon.mcnamara@seattlechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Active, not recruiting
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Part A - children with confirmed diagnosis of cystic fibrosis who are less than 5 years of age and not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy
Part B - children with confirmed diagnosis of cystic fibrosis who are less than 6 years of age (or participated in Part A of the study) with an intention to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy
Description
Inclusion Criteria:
Part A:
- Less than 5 years of age at the first study visit.
- Documentation of a CF diagnosis.
Part B:
- Participated in Part A OR less than 6 years of age at the first study visit.
- Documentation of a CF diagnosis.
- CFTR mutations consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor).
- Physician intent to prescribe ivacaftor or elexacaftor/tezacaftor/ivacaftor.
Exclusion Criteria:
- Part A and Part B:
Use of an investigational drug within 28 days prior to and including the first study visit.
Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 180 days prior to and including the first study visit.
Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Part A
Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
|
|
Part B
Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
|
In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A Primary Outcome Measure: Change in weight-for-age z-scores
Time Frame: Baseline to 12 months
|
Weight-for-age z-scores over time
|
Baseline to 12 months
|
Part A Primary Outcome Measure: Change in height-for-age z-scores
Time Frame: Baseline to 12 months
|
Height-for-age z-scores over time
|
Baseline to 12 months
|
Part B Primary Outcome Measure: Change in weight-for-age z-scores
Time Frame: 1, 3, 6, 12, and 24 months
|
Change in weight-for-age z-scores from baseline
|
1, 3, 6, 12, and 24 months
|
Part B Primary Outcome Measure: Change in height-for-age z-scores
Time Frame: 1, 3, 6, 12, and 24 months
|
Change in height-for-age z-scores from baseline
|
1, 3, 6, 12, and 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Chloride Channel Agonists
- Ivacaftor
- Elexacaftor
Other Study ID Numbers
- BEGIN-OB-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Ivacaftor or elexacaftor/tezacaftor/ivacaftor
-
Charite University, Berlin, GermanyHannover Medical School; Heidelberg University; University of GiessenRecruiting
-
University of California, Los AngelesUniversity of Iowa; Children's Hospital Colorado; University of Kansas Medical... and other collaboratorsRecruitingChronic Rhinosinusitis (Diagnosis) | Cystic Fibrosis | Olfactory Disorder | Cystic Fibrosis in Children | Olfactory ImpairmentUnited States
-
University of British ColumbiaRecruiting
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationRecruiting
-
Jennifer Taylor-CousarCystic Fibrosis FoundationRecruiting
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisBelgium, United Kingdom, Australia, Germany
-
University of British ColumbiaRecruiting
-
University Hospital, Strasbourg, FranceNot yet recruiting
-
University of Erlangen-Nürnberg Medical SchoolRecruitingCystic FibrosisGermany